- |||||||||| Libtayo (cemiplimab-rwlc) / Regeneron
Biomarker, Enrollment open, PD(L)-1 Biomarker, IO biomarker, Immunomodulating, Metastases, Biopsy: An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Patients With Head and Neck Cancer Receiving REGN2810 (Anti-PD-1) (clinicaltrials.gov) - Jun 26, 2017 P1, N=30, Recruiting, Recruiting --> Suspended Not yet recruiting --> Recruiting
- |||||||||| Libtayo (cemiplimab-rwlc) / Regeneron
Biomarker, New P1 trial, PD(L)-1 Biomarker, IO biomarker, Immunomodulating, Metastases, Biopsy: An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Patients With Head and Neck Cancer Receiving REGN2810 (Anti-PD-1) (clinicaltrials.gov) - Jun 22, 2017 P1, N=30, Not yet recruiting,
- |||||||||| Libtayo (cemiplimab) / Regeneron
Biomarker, Enrollment open, Trial initiation date, PD(L)-1 Biomarker, IO biomarker, Immunomodulating, Biopsy: An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Melanoma Patients Receiving REGN2810 (Anti-PD-1) (clinicaltrials.gov) - Apr 14, 2017 P1, N=30, Recruiting, Not yet recruiting --> Recruiting | Initiation date: Mar 2017 --> May 2017 Not yet recruiting --> Recruiting | Initiation date: Jan 2017 --> Apr 2017
- |||||||||| Libtayo (cemiplimab-rwlc) / Regeneron
Enrollment change, Trial primary completion date, Combination therapy, Metastases: Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies (clinicaltrials.gov) - Dec 21, 2016 P1, N=560, Recruiting, Initiation date: Jan 2017 --> Jun 2017 | Trial primary completion date: Jan 2017 --> Jan 2021 N=973 --> 560 | Trial primary completion date: Dec 2018 --> Jul 2019
|